{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:18:55Z","timestamp":1790684335816,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T00:00:00Z","timestamp":1699574400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T00:00:00Z","timestamp":1699574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 32171277"],"award-info":[{"award-number":["No. 32171277"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Nucleoside analogues are currently applied as a first-line treatment for chronic hepatitis B (CHB) patients. However, the long-term effects of this type of treatment on kidney and bone tissue need to be further investigated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a search of entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide fumarate (TAF) for treatment of CHB patients through October 29, 2023. Side effects of the three drugs were compared. Standardized mean difference (SMD), 95% confidence interval (95%CI), and surface under the cumulative ranking curve (SUCRA) were reported for each outcome. Further subgroup analysis was conducted according to duration of administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>ETV and TAF exhibited less effect on estimated glomerular filtration rate (eGFR) than TDF (SMD = -3.60 (95%CI: -1.94 ~ -5.26) and SMD = -4.27 (95%CI: -2.62 ~ -5.93)). ETV also exhibited less effect on creatinine rise than TAF and TDF (SMD = -0.55 (95%CI: -0.09 ~ -1.01) and SMD = -0.61 (95%CI: -0.15 ~ -1.06)). Moreover, the effect of TAF on bone mineral density (BMD) was less than that of TDF (SMD = -0.02 (95%CI: -0.01 ~ -0.02)). The probabilities of the three drugs changing relevant indicators exhibited similar patterns: eGFR (TDF (100.0%)\u2009&gt;\u2009ETV (41.2%)\u2009&gt;\u2009TAF (8.8%)), creatinine (TDF (94.7%)\u2009&gt;\u2009TAF (54.7%)\u2009&gt;\u2009ETV (0.6%)), BMD (TDF (79.7%)\u2009&gt;\u2009ETV (50.6%)\u2009&gt;\u2009TAF (19.6%)), and blood phosphorus (TDF (90.6%)\u2009&gt;\u2009TAF (49.8%)\u2009&gt;\u2009ETV (9.7%)). After 6 and 24 months of treatment, no statistically significant difference in renal function or bone tissue was observed between ETV and TDF. However, greater adverse effects on renal function were observed for TDF than ETV at 60 months compared to 12 months. TDF also exhibited greater adverse effects on bone tissue than ETV at 36 months than at 12 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Long-term administration of TDF has resulted in stronger adverse effects than TAF and ETV in regard to both renal function and bone tissue in CHB patients. The effect of TAF on creatinine increase was greater than ETV. The difference in side effects between ETV and TDF was independent of treatment duration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-023-03027-4","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T08:02:34Z","timestamp":1699603354000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis"],"prefix":"10.1186","volume":"23","author":[{"given":"Zekun","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shousheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongning","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,10]]},"reference":[{"key":"3027_CR1","doi-asserted-by":"crossref","unstructured":"Tu T, Douglas MW. Hepatitis B Virus Infection: from Diagnostics to treatments. Viruses, 2020. 12(12).","DOI":"10.3390\/v12121366"},{"issue":"7","key":"3027_CR2","first-page":"545","volume":"4","author":"PA Revill","year":"2019","unstructured":"Revill PA, et al. A global scientific strategy to cure Hepatitis B the Lancet. Gastroenterol Hepatol. 2019;4(7):545\u201358.","journal-title":"Gastroenterol Hepatol"},{"key":"3027_CR3","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.ejmech.2018.02.001","volume":"147","author":"D Sun","year":"2018","unstructured":"Sun D, et al. Recent progress in potential anti-hepatitis B virus agents: structural and pharmacological perspectives. Eur J Med Chem. 2018;147:205\u201317.","journal-title":"Eur J Med Chem"},{"key":"3027_CR4","doi-asserted-by":"crossref","unstructured":"EASL 2017 clinical practice guidelines on the management of Hepatitis B virus Infection. J Hepatol, 2017. 67(2): p. 370\u201398.","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"3027_CR5","doi-asserted-by":"publisher","first-page":"18035","DOI":"10.1038\/nrdp.2018.35","volume":"4","author":"M-F Yuen","year":"2018","unstructured":"Yuen M-F, et al. Hepatitis B virus Infection. Nat Reviews Disease Primers. 2018;4:18035.","journal-title":"Nat Reviews Disease Primers"},{"key":"3027_CR6","doi-asserted-by":"crossref","unstructured":"Lee HW, Lee JS, Ahn SH. Hepatitis B Virus Cure: targets and future therapies. Int J Mol Sci, 2020. 22(1).","DOI":"10.3390\/ijms22010213"},{"key":"3027_CR7","doi-asserted-by":"crossref","unstructured":"Nicolini LA et al. A Global View to HBV chronic Infection: evolving strategies for diagnosis, Treatment and Prevention in Immunocompetent individuals. Int J Environ Res Public Health, 2019. 16(18).","DOI":"10.3390\/ijerph16183307"},{"key":"3027_CR8","doi-asserted-by":"crossref","unstructured":"Vigan\u00f2 M et al. Treatment of Hepatitis B: is there still a role for interferon? Liver International: Official Journal of the International Association for the study of the liver, 2018. 38 Suppl 1: p. 79\u201383.","DOI":"10.1111\/liv.13635"},{"key":"3027_CR9","doi-asserted-by":"crossref","unstructured":"Chien R-N, Liaw Y-F. Current Trend in Antiviral Therapy for Chronic Hepatitis B. Viruses, 2022. 14(2).","DOI":"10.3390\/v14020434"},{"key":"3027_CR10","doi-asserted-by":"crossref","unstructured":"Nguyen MH et al. Hepatitis B Virus: advances in Prevention, diagnosis, and Therapy. Clin Microbiol Rev, 2020. 33(2).","DOI":"10.1128\/CMR.00046-19"},{"issue":"9959","key":"3027_CR11","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1016\/S0140-6736(14)60220-8","volume":"384","author":"C Tr\u00e9po","year":"2014","unstructured":"Tr\u00e9po C, Chan HLY, Lok A. Hepatitis B virus Infection. Lancet (London England). 2014;384(9959):2053\u201363.","journal-title":"Lancet (London England)"},{"key":"3027_CR12","doi-asserted-by":"crossref","unstructured":"Jeong S, Shin HP, Kim HI. Real-world single-center comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in patients with chronic Hepatitis B. Intervirology, 2022. 65(2).","DOI":"10.1159\/000519440"},{"issue":"11","key":"3027_CR13","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1038\/ki.2010.344","volume":"78","author":"MA Perazella","year":"2010","unstructured":"Perazella MA. Tenofovir-induced Kidney Disease: an acquired renal tubular mitochondriopathy. Kidney Int. 2010;78(11):1060\u20133.","journal-title":"Kidney Int"},{"issue":"2","key":"3027_CR14","first-page":"273","volume":"82","author":"AV Kara","year":"2019","unstructured":"Kara AV, et al. Effects of entecavir, tenofovir and telbivudine treatment on renal functions in chronic Hepatitis B patients. Acta Gastroenterol Belg. 2019;82(2):273\u20137.","journal-title":"Acta Gastroenterol Belg"},{"key":"3027_CR15","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.intimp.2016.11.022","volume":"42","author":"Y Han","year":"2017","unstructured":"Han Y, et al. The efficacy and safety comparison between tenofovir and entecavir in treatment of chronic Hepatitis B and HBV related Cirrhosis: a systematic review and Meta-analysis. Int Immunopharmacol. 2017;42:168\u201375.","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"3027_CR16","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/jgh.12499","volume":"29","author":"J Fung","year":"2014","unstructured":"Fung J, et al. Extrahepatic effects of nucleoside and nucleotide analogues in chronic Hepatitis B treatment. J Gastroenterol Hepatol. 2014;29(3):428\u201334.","journal-title":"J Gastroenterol Hepatol"},{"issue":"5","key":"3027_CR17","first-page":"314","volume":"99","author":"T Wilkins","year":"2019","unstructured":"Wilkins T, Sams R, Carpenter M. Hepatitis B: Screening, Prevention, diagnosis, and treatment. Am Family Phys. 2019;99(5):314\u201323.","journal-title":"Am Family Phys"},{"issue":"11","key":"3027_CR18","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1111\/j.1365-2036.2012.05093.x","volume":"35","author":"N Gara","year":"2012","unstructured":"Gara N, et al. Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic Hepatitis B. Aliment Pharmacol Ther. 2012;35(11):1317\u201325.","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"3027_CR19","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/j.1468-1293.2009.00716.x","volume":"10","author":"CLN Woodward","year":"2009","unstructured":"Woodward CLN, et al. Tenofovir-associated renal and bone toxicity. HIV Med. 2009;10(8):482\u20137.","journal-title":"HIV Med"},{"issue":"3","key":"3027_CR20","first-page":"324","volume":"9","author":"J Hou","year":"2021","unstructured":"Hou J, et al. 3-year treatment of Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate for chronic HBV Infection in China. J Clin Translational Hepatol. 2021;9(3):324\u201334.","journal-title":"J Clin Translational Hepatol"},{"issue":"7","key":"3027_CR21","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1002\/jmv.25442","volume":"91","author":"A Iida-Ueno","year":"2019","unstructured":"Iida-Ueno A, et al. Switching to tenofovir disoproxil fumarate vs continuing treatment in patients with chronic Hepatitis B who maintain long-term virological response to entecavir therapy: a randomized trial. J Med Virol. 2019;91(7):1295\u2013300.","journal-title":"J Med Virol"},{"key":"3027_CR22","doi-asserted-by":"crossref","unstructured":"Seto W-K, et al. Improved Bone Safety of Tenofovir Alafenamide Compared to Tenofovir Disoproxil Fumarate Over 2 Years in Patients With Chronic HBV Infection Clinical Gastroenterology and Hepatology: the Official Clinical. Practice Journal of the American Gastroenterological Association; 2018.","DOI":"10.1016\/j.cgh.2018.06.023"},{"key":"3027_CR23","doi-asserted-by":"crossref","unstructured":"Byun KS et al. Tenofovir Alafenamide for Drug-Resistant Hepatitis B: a Randomized Trial for switching from Tenofovir Disoproxil Fumarate. Clin Gastroenterol Hepatology: Official Clin Pract J Am Gastroenterological Association, 2022. 20(2).","DOI":"10.1016\/j.cgh.2021.04.045"},{"issue":"6","key":"3027_CR24","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1111\/liv.14786","volume":"41","author":"Z-B Li","year":"2021","unstructured":"Li Z-B, et al. Switching from entecavir to tenofovir alafenamide for chronic Hepatitis B patients with low-level viraemia. Liver International: Official Journal of the International Association for the Study of the Liver. 2021;41(6):1254\u201364.","journal-title":"Liver International: Official Journal of the International Association for the Study of the Liver"},{"issue":"5","key":"3027_CR25","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1053\/j.ajkd.2021.04.016","volume":"78","author":"LA Inker","year":"2021","unstructured":"Inker LA, Titan S. Measurement and estimation of GFR for Use in Clinical Practice: Core Curriculum 2021. Am J Kidney Diseases: Official J Natl Kidney Foundation. 2021;78(5):736\u201349.","journal-title":"Am J Kidney Diseases: Official J Natl Kidney Foundation"},{"key":"3027_CR26","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.2147\/TCRM.S143286","volume":"13","author":"Y-M Yang","year":"2017","unstructured":"Yang Y-M, Choi EJ. Renal safety of tenofovir and\/or entecavir in patients with chronic HBV monoinfection. Ther Clin Risk Manag. 2017;13:1273\u201385.","journal-title":"Ther Clin Risk Manag"},{"issue":"1","key":"3027_CR27","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/apt.13659","volume":"44","author":"P Lampertico","year":"2016","unstructured":"Lampertico P, et al. Review article: long-term safety of nucleoside and nucleotide analogues in HBV-monoinfected patients. Aliment Pharmacol Ther. 2016;44(1):16\u201334.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"3027_CR28","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1007\/s12325-016-0337-2","volume":"33","author":"HLY Chan","year":"2016","unstructured":"Chan HLY, et al. Renal function in Nucleos(t)ide Analog-treated patients with chronic Hepatitis B: a systematic literature review and network Meta-analysis. Adv Therapy. 2016;33(5):862\u201375.","journal-title":"Adv Therapy"},{"issue":"Suppl 1","key":"3027_CR29","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/liv.13641","volume":"38","author":"M Buti","year":"2018","unstructured":"Buti M, Riveiro-Barciela M, Esteban R. Long-term safety and efficacy of nucleo(t)side analogue therapy in Hepatitis B. Liver International: Official Journal of the International Association for the Study of the Liver. 2018;38(Suppl 1):84\u20139.","journal-title":"Liver International: Official Journal of the International Association for the Study of the Liver"},{"key":"3027_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2016.04.015","volume":"119","author":"E De Clercq","year":"2016","unstructured":"De Clercq E. Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF). Biochem Pharmacol. 2016;119:1\u20137.","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"3027_CR31","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1097\/QAI.0b013e3182965d45","volume":"63","author":"PJ Ruane","year":"2013","unstructured":"Ruane PJ, et al. Antiviral activity, safety, and pharmacokinetics\/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. J Acquir Immune Defic Syndr. 2013;63(4):449\u201355.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"3027_CR32","doi-asserted-by":"crossref","unstructured":"Sax PE et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials Lancet (London, England), 2015. 385(9987): p.\u00a02606\u20132615.","DOI":"10.1016\/S0140-6736(15)60616-X"},{"issue":"1","key":"3027_CR33","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12981-021-00380-w","volume":"18","author":"T Ueaphongsukkit","year":"2021","unstructured":"Ueaphongsukkit T, et al. Tenofovir alafenamide nephrotoxicity: a case report and literature review. AIDS Res Therapy. 2021;18(1):53.","journal-title":"AIDS Res Therapy"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-023-03027-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-023-03027-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-023-03027-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T08:04:40Z","timestamp":1699603480000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-023-03027-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,10]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3027"],"URL":"https:\/\/doi.org\/10.1186\/s12876-023-03027-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2788603\/v1","asserted-by":"object"}]},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,10]]},"assertion":[{"value":"7 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"384"}}